Delayed diagnosis of active pulmonary tuberculosis - potential risk factors for patient and healthcare delays in Portugal

Abstract

Background Early diagnosis and treatment of pulmonary tuberculosis (PTB) is essential for an effective control of the tuberculosis (TB) epidemic. Delayed diagnosis and treatment of TB increases the chance of complications and mortality for the patients, and enhances TB transmission in the population. Therefore, the aim of this study was to characterize patient, healthcare and total delay in diagnosing PTB and assess the effect of clinical and sociodemographic factors on the time until first contact with healthcare or reaching a PTB diagnosis. Methods Retrospective cohort study that included active PTB patients notified in the National Tuberculosis Surveillance System (SVIG-TB), between 2008 and 2017. Descriptive statistics, Kaplan-Meier estimates, logrank test and Cox proportional hazards model were used to characterize patient, healthcare and total delay and estimate the effect of clinical and sociodemographic variables on these delays. Significance level was set at 0.05. Results Median patient, healthcare and total delays was 37 days (Interquartile range (IQR): 19–71), 8 days (IQR: 1–32) and 62 days (IQR: 38–102), respectively. The median patient delay showed a constant increase, from 33 days in 2008 to 44 days in 2017. The median total delay presented a similar trend, increasing from 59 days in 2008 to 70 days in 2017. Healthcare delay remained constant during the study period. More than half of the PTB cases (82.9%) had a delay > 1 month between symptom onset and diagnosis. In the final Cox model, alcohol abuse, unemployment and being from a high TB incidence country were factors significantly associated with longer patient delay, while being female, having more than 45 years, oncologic and respiratory diseases were associated with longer healthcare delay. Being female, having more than 45 years and being from a high TB incidence country were associated with longer total delay. Conclusions Patient delay and total delay have increased in recent years. Older patients, patients with alcohol problems, other comorbidities, unemployed or from countries with high TB incidence would benefit from the development of specific public health strategies that could help reduce the delay in TB diagnosis observed in our study. This study emphasizes the need to promote awareness of TB in the general population and among the healthcare community, especially at ambulatory care level, in order to reduce the gap between beginning of symptoms and TB diagnosis.

Disseminated tuberculosis and diagnosis delay during the COVID-19 era in a Western European country: a case series analysis

“…Women may experience the factors described with higher intensity. The delay in diagnosis tends to be more pronounced for women with pulmonary involvement, which is a more easily diagnosable TB form than it is for men, according to a recent study in Portugal ( 27 ). Women’s access to healthcare is limited and often dependent on their husbands, and they are likely to face greater language barriers ( 28 ).…”

Evolution of tuberculosis diagnostics: From molecular strategies to nanodiagnostics

“…Delayed diagnosis accelerates infection severity, increases the risk of mortality, and enables the transmission of bacilli within the healthy community. Further, incorrect diagnosis will lead to imprecise treatment therapy that will eventually lead to development of drug-resistant in the infected individual [ 106 ]. Thus, rapid, highly sensitive and specific diagnostic tests and approaches need to be explored for detection of Mtb .…”

Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis Based on Bronchoalveolar Lavage Fluid: A Systematic Review and Meta-analysis

“…1 Early intervention of pulmonary TB (PTB) can effectively control transmission and the TB epidemic. 2 Pulmonary TB is an infectious disease that can be spread by droplets and is caused by Mycobacterium tuberculosis (MTB). The pathogen enters the respiratory tract and is ingested by macrophages; however, MTB is able to continue multiplication within the infected macrophages.…”

“…In recent years, TB ranked second only to COVID-19 as a cause of death from a single infectious agent, which therefore imposes a significant public health burden 1 . Early intervention of pulmonary TB (PTB) can effectively control transmission and the TB epidemic 2 …”